Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVenture Life Regulatory News (VLG)

Share Price Information for Venture Life (VLG)

Share Price is delayed by 15 minutes
Get Live Data
66.50    0.00 (0.00%)
Bid:
66.00
Ask:
67.00
Spread: 1.00 (1.515%)
Market Cap: £80.67m
VLG Live PriceLast checked at - London Stock Exchange

Intraday Venture Life Share Chart

UltraDEX advertising launch

10 Oct 2016 07:00

RNS Number : 0358M
Venture Life Group PLC
10 October 2016
Β 

Venture Life Group plc

("Venture Life" or the "Company")

Β 

UltraDEX advertising launch

Β 

Venture Life (AIM: VLG), the international consumer self-care group focused on developing, manufacturing and commercialising products for the ageing population, announces the launch of the new UltraDEX advertising campaign in the UK.

Β 

Since the acquisition of the UltraDEX oral care products range in March 2016, the Company has revitalised the brand, creating a fresh identity and a clearer message on all advertising material and packaging. The range is comprised of a daily oral rinse, toothpaste, oral spray and other inter-dental accessories, and achieved revenues of Β£1.4 million in the first six months of 2016. The Company's Brands business now represents 20% of its total revenue and the Company remains confident in the growth prospects for UltraDEX, in addition to its other brands, having signed three new distribution agreements for UltraDEX since acquiring it in March 2016.

Β 

The campaign, launching today, will run for two weeks and aims to increase brand awareness and encourage product trial among new users. UltraDEX will feature on approximately 4,000 tube cards on the London Underground, meaning a banner advertisement in every train carriage on every line, as well as cross track posters in 91 Underground stations. In conjunction with this, the Company will run an extensive radio campaign in London and the South East and free UltraDEX samples will be given out at Waterloo, Victoria and Liverpool Street stations. A new website (www.ultradex.co.uk) has also been launched and whilst the overall level of advertising is significant for Venture Life it is in line with budgeted plans. It will also support in-store activity amongst Venture Life's key retail partners such as Boots, Tesco, Sainsbury's and Amazon, as the Company continues to grow the retail presence of the brand.

Β 

Commenting, Chief Executive Officer of Venture Life, Jerry Randall, said: "The acquisition of UltraDEX has had a big impact on our Brands business and we are expecting it to make a significant contribution towards Group profitability. This campaign is being run initially in the London and South East region as we continue to invest behind the UltraDEX brand and support our retail partners."

Β 

If any investors would like a sample of the UltraDEX products, please contact Walbrook PR using the contact details below.

Β 

For further information, please contact:

Venture Life Group PLC

+44 (0) 1344 742870

Jerry Randall, Chief Executive Officer

Β 

James Hunter, Chief Financial Officer

Β 

Β 

Β 

Panmure Gordon (UK) Limited (Nominated Adviser and Joint Broker)

+44 (0) 20 7886 2500

Freddy Crossley/Peter Steel/Duncan Monteith (Corporate Finance)

Β 

Tom Salvesen (Corporate Broking)

Β 

Β 

Turner Pope Investments (TPI) Ltd (Joint Broker)

+44 (0) 20 3621 4120

James Pope/Ben Turner

Β 

Β 

Walbrook PR

venturelife@walbrookpr.com or +44 (0) 20 7933 8780

Paul McManus/Anna Dunphy

+44 (0) 7980 541 893 / +44 (0) 7876 741 001

Β 

Β 

Β 

About Venture Life (www.venture-life.com)

Β 

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the ageing population. The Group's product range and pipeline currently includes the UltraDEX oral care products range, food supplements for lowering cholesterol and maintaining brain function, dermo-cosmetics for addressing the signs of ageing, and medical devices for improving minor aches and pains, dry eyes and itchy skin.

Β 

The products, which typically are recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners.

Β 

Through its manufacturing company, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
NRAZDLFBQBFEFBE
Date   Source Headline
10th Jun 202212:21 pmRNSDirector/PDMR Shareholding
9th Jun 20225:53 pmRNSAnnual Report & Notice of AGM - Correction
7th Jun 20227:00 amRNSAnnual Report & Notice of AGM
30th May 20224:22 pmRNSDirector/PDMR Shareholding
30th May 20227:00 amRNSDirectorate Changes
23rd May 20224:27 pmRNSHolding(s) in Company
20th May 20227:00 amRNSInvestor Presentation
17th May 20227:00 amRNSDirectorate Changes
17th May 20227:00 amRNSFinal Results
10th May 202211:31 amRNSExercise of Share Options & Voting Rights
19th Apr 20227:00 amRNSReporting Update
23rd Mar 20223:00 pmRNSAnnouncement re: Full year results
22nd Feb 20227:00 amRNSGrant of Options and PDMR Dealing
21st Feb 20227:00 amRNSResults - clinical trial led by Cardiff University
31st Jan 20224:41 pmRNSSecond Price Monitoring Extn
31st Jan 20224:37 pmRNSPrice Monitoring Extension
31st Jan 20222:06 pmRNSSecond Price Monitoring Extn
31st Jan 20222:01 pmRNSPrice Monitoring Extension
31st Jan 20227:00 amRNSTrading Statement
24th Jan 20222:06 pmRNSSecond Price Monitoring Extn
24th Jan 20222:00 pmRNSPrice Monitoring Extension
10th Jan 20227:00 amRNSBusiness Update
29th Dec 202112:34 pmRNSDirector/PDMR Shareholding
20th Dec 20214:13 pmRNSDirectorate Change
14th Dec 202111:05 amRNSSecond Price Monitoring Extn
14th Dec 202111:01 amRNSPrice Monitoring Extension
3rd Dec 20214:22 pmRNSDirector/PDMR Shareholding
1st Dec 20219:06 amRNSSecond Price Monitoring Extn
1st Dec 20219:00 amRNSPrice Monitoring Extension
1st Dec 20217:00 amRNSTrading Update & Board Changes
1st Nov 20212:00 pmRNSPrice Monitoring Extension
1st Nov 20218:44 amRNSHolding(s) in Company
1st Nov 20218:43 amRNSHolding(s) in Company
25th Oct 20217:00 amRNSHolding(s) in Company
11th Oct 20212:41 pmRNSHolding(s) in Company
23rd Sep 20219:05 amRNSSecond Price Monitoring Extn
23rd Sep 20219:00 amRNSPrice Monitoring Extension
23rd Sep 20217:00 amRNSHalf-year Report
7th Sep 20211:54 pmRNSHolding(s) in Company
13th Aug 20219:05 amRNSSecond Price Monitoring Extn
13th Aug 20219:00 amRNSPrice Monitoring Extension
13th Aug 20217:00 amRNSTrading Update and Progress on recent Acquisitions
6th Aug 20217:00 amRNSAcquisition of Oncology Support Product Assets
21st Jun 20217:00 amRNSRevolving Credit Facility
7th Jun 20217:00 amRNSAcquisition of BBI Healthcare Limited
20th May 20212:29 pmRNSResult of AGM
14th Apr 20214:19 pmRNSHolding(s) in Company
25th Mar 20212:19 pmRNSConfirmation of AGM Date
25th Mar 20217:00 amRNSFinal Results
25th Feb 20217:00 amRNSInvestor Presentation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.